Various scenarios have been reported for different AML samples and markers at diagnostic compared to relapse samples (e.g., TIM-3 [24], CLL-1 [55], GPR56: with similar [55] or higher expression [93]), in line with the possibility that relapse-driving therapy-resistant minor clones and their LSC are already present at diagnosis and then survive therapies to cause deadly relapse (Figure 2). Here, ADGRG1 is linked to acute myeloid leukemia.